132 related articles for article (PubMed ID: 27221729)
1. Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors.
Nijenhuis CM; Hellriegel E; Beijnen JH; Hershock D; Huitema AD; Lucas L; Mergui-Roelvink M; Munteanu M; Rabinovich-Guilatt L; Robertson P; Rosing H; Spiegelstein O; Schellens JH
Invest New Drugs; 2016 Oct; 34(5):565-74. PubMed ID: 27221729
[TBL] [Abstract][Full Text] [Related]
2. Metabolite profiling of
Nijenhuis CM; Lucas L; Rosing H; Robertson P; Hellriegel ET; Schellens JH; Beijnen AJ
Xenobiotica; 2016 Dec; 46(12):1122-1132. PubMed ID: 26998885
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.
Nemunaitis J; Mita A; Stephenson J; Mita MM; Sarantopoulos J; Padmanabhan-Iyer S; Nanda N; Gleich L; Benichou AC; Craig A
Cancer Chemother Pharmacol; 2013 Jan; 71(1):35-41. PubMed ID: 23053254
[TBL] [Abstract][Full Text] [Related]
4. Validation of high-performance liquid chromatography-tandem mass spectrometry assays quantifying omacetaxine mepesuccinate and its 4'‑des-methyl and cephalotaxine metabolites in human plasma and urine.
Nijenhuis CM; Lucas L; Rosing H; Schellens JH; Beijnen JH; Gorman SH; Burke SM; Campbell DA; Chapple MW; Yousey TH; Mulvana DE
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Oct; 1002():152-9. PubMed ID: 26319804
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.
Cortes J; Digumarti R; Parikh PM; Wetzler M; Lipton JH; Hochhaus A; Craig AR; Benichou AC; Nicolini FE; Kantarjian HM;
Am J Hematol; 2013 May; 88(5):350-4. PubMed ID: 23468307
[TBL] [Abstract][Full Text] [Related]
6. Omacetaxine mepesuccinate--a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies.
Quintás-Cardama A; Cortes J
IDrugs; 2008 May; 11(5):356-72. PubMed ID: 18465678
[TBL] [Abstract][Full Text] [Related]
7. Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate.
Akard L; Kantarjian HM; Nicolini FE; Wetzler M; Lipton JH; Baccarani M; Jean Khoury H; Kurtin S; Li E; Munteanu M; Cortes J
Leuk Lymphoma; 2016; 57(3):654-65. PubMed ID: 26436949
[TBL] [Abstract][Full Text] [Related]
8. Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II.
Nijenhuis CM; Lucas L; Rosing H; Huitema ADR; Mergui-Roelvink M; Jamieson GC; Fox JA; Mould DR; Schellens JHM; Beijnen JH
Invest New Drugs; 2017 Aug; 35(4):478-490. PubMed ID: 28138829
[TBL] [Abstract][Full Text] [Related]
9. Omacetaxine mepesuccinate for the treatment of leukemia.
Kim TD; Frick M; le Coutre P
Expert Opin Pharmacother; 2011 Oct; 12(15):2381-92. PubMed ID: 21916787
[TBL] [Abstract][Full Text] [Related]
10. Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up.
Cortes JE; Kantarjian HM; Rea D; Wetzler M; Lipton JH; Akard L; Khoury HJ; Michallet M; Guerci-Bresler A; Chuah C; Hellmann A; Digumarti R; Parikh PM; Legros L; Warzocha K; Baccarani M; Li E; Munteanu M; Nicolini FE
Cancer; 2015 May; 121(10):1637-44. PubMed ID: 25586015
[TBL] [Abstract][Full Text] [Related]
11. A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
Damlaj M; Lipton JH; Assouline SE
Expert Opin Drug Saf; 2016 Sep; 15(9):1279-86. PubMed ID: 27367461
[TBL] [Abstract][Full Text] [Related]
12. Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.
Rosshandler Y; Shen AQ; Cortes J; Khoury HJ
Expert Rev Hematol; 2016 May; 9(5):419-24. PubMed ID: 26853281
[TBL] [Abstract][Full Text] [Related]
13. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [
Zhou X; Pusalkar S; Chowdhury SK; Searle S; Li Y; Ullmann CD; Venkatakrishnan K
Invest New Drugs; 2019 Aug; 37(4):666-673. PubMed ID: 30397836
[TBL] [Abstract][Full Text] [Related]
14. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.
Dubbelman AC; Rosing H; Jansen RS; Mergui-Roelvink M; Huitema AD; Koetz B; Lymboura M; Reyderman L; Lopez-Anaya A; Schellens JH; Beijnen JH
Drug Metab Dispos; 2012 Feb; 40(2):313-21. PubMed ID: 22041109
[TBL] [Abstract][Full Text] [Related]
15. A phase I study to assess the mass balance, excretion, and pharmacokinetics of [
Gupta N; Zhang S; Pusalkar S; Plesescu M; Chowdhury S; Hanley MJ; Wang B; Xia C; Zhang X; Venkatakrishnan K; Shepard DR
Invest New Drugs; 2018 Jun; 36(3):407-415. PubMed ID: 28932928
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of absorption, distribution, metabolism, and excretion of [
Liao M; Watkins S; Nash E; Isaacson J; Etter J; Beltman J; Fan R; Shen L; Mutlib A; Kemeny V; Pápai Z; van Tilburg P; Xiao JJ
Invest New Drugs; 2020 Jun; 38(3):765-775. PubMed ID: 31250355
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy.
Dubbelman AC; Rosing H; Darwish M; D'Andrea D; Bond M; Hellriegel E; Robertson P; Beijnen JH; Schellens JH
Drugs R D; 2013 Mar; 13(1):17-28. PubMed ID: 23322528
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and excretion of (14)C-lenvatinib in patients with advanced solid tumors or lymphomas.
Dubbelman AC; Rosing H; Nijenhuis C; Huitema AD; Mergui-Roelvink M; Gupta A; Verbel D; Thompson G; Shumaker R; Schellens JH; Beijnen JH
Invest New Drugs; 2015 Feb; 33(1):233-40. PubMed ID: 25377392
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and excretion of
van Andel L; Fudio S; Rosing H; Munt S; Miguel-Lillo B; González I; Tibben MM; de Vries N; de Vries Schultink AHM; Schellens JHM; Beijnen JH
Invest New Drugs; 2017 Oct; 35(5):589-598. PubMed ID: 28111728
[TBL] [Abstract][Full Text] [Related]
20. Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
Narayanan V; Gutman JA; Pollyea DA; Jimeno A
Drugs Today (Barc); 2013 Jul; 49(7):447-56. PubMed ID: 23914353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
